32 related articles for article (PubMed ID: 30692043)
1. Hepatocyte Deletion of IGF2 Prevents DNA Damage and Tumor Formation in Hepatocellular Carcinoma.
Kumar D; Das M; Oberg A; Sahoo D; Wu P; Sauceda C; Jih L; Ellies LG; Langiewicz MT; Sen S; Webster NJG
Adv Sci (Weinh); 2022 Jul; 9(21):e2105120. PubMed ID: 35615981
[TBL] [Abstract][Full Text] [Related]
2. Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma.
Yao M; Yang JL; Wang DF; Wang L; Chen Y; Yao DF
World J Clin Cases; 2022 Apr; 10(11):3321-3333. PubMed ID: 35611205
[TBL] [Abstract][Full Text] [Related]
3. The Interplay Between Non-coding RNAs and Insulin-Like Growth Factor Signaling in the Pathogenesis of Neoplasia.
Ghafouri-Fard S; Abak A; Mohaqiq M; Shoorei H; Taheri M
Front Cell Dev Biol; 2021; 9():634512. PubMed ID: 33768092
[TBL] [Abstract][Full Text] [Related]
4. Tumor-associated macrophages promote human hepatoma Huh-7 cell migration and invasion through the Gli2/IGF-II/ERK1/2 axis by secreting TGF-β1.
Liu M; Zhong YB; Shao J; Zhang C; Shi C
Cancer Biol Ther; 2020 Nov; 21(11):1041-1050. PubMed ID: 33081566
[TBL] [Abstract][Full Text] [Related]
5. [Correlation between epigenetic alterations in the insulin growth factor-II gene and hepatocellular carcinoma].
Dong ZZ; Yao DF; Wu W; Qiu LW; Yao NH; Yan XD; Yu DD; Chen J
Zhonghua Gan Zang Bing Za Zhi; 2012 Aug; 20(8):593-7. PubMed ID: 23207153
[TBL] [Abstract][Full Text] [Related]
6. Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma.
Dong ZZ; Yao DF; Yao DB; Wu XH; Wu W; Qiu LW; Jiang DR; Zhu JH; Meng XY
World J Gastroenterol; 2005 Aug; 11(30):4655-60. PubMed ID: 16094705
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of insulin-like growth factor-I receptor as a pertinent biomarker for hepatocytes malignant transformation.
Yan XD; Yao M; Wang L; Zhang HJ; Yan MJ; Gu X; Shi Y; Chen J; Dong ZZ; Yao DF
World J Gastroenterol; 2013 Sep; 19(36):6084-92. PubMed ID: 24106410
[TBL] [Abstract][Full Text] [Related]
8. Abnormal expression of insulin-like growth factor-II and its dynamic quantitative analysis at different stages of hepatocellular carcinoma development.
Qiu LW; Yao DF; Zong L; Lu YY; Huang H; Wu W; Wu XH
Hepatobiliary Pancreat Dis Int; 2008 Aug; 7(4):406-11. PubMed ID: 18693177
[TBL] [Abstract][Full Text] [Related]
9. [Hepatitis B virus X protein promotes insulin-like growth factor II gene expression by inducing hypomethylation of the P3 promoter in hepatocellular carcinoma].
Tang S; Zhang S; Zhang X; Wu S; Li J; Jiang X; Zhou H; Luo Y; Cao M
Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):289-94. PubMed ID: 25173229
[TBL] [Abstract][Full Text] [Related]
10. Alteration of oncogenic IGF-II gene methylation status associates with hepatocyte malignant transformation.
Tai BJ; Yao M; Zheng WJ; Shen YC; Wang L; Sun JY; Wu MN; Dong ZZ; Yao DF
Hepatobiliary Pancreat Dis Int; 2019 Apr; 18(2):158-163. PubMed ID: 30692043
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of DNA methylation in hepatocellular carcinoma.
Sceusi EL; Loose DS; Wray CJ
HPB (Oxford); 2011 Jun; 13(6):369-76. PubMed ID: 21609368
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like Growth Factor I Receptor: A Novel Target for Hepatocellular Carcinoma Gene Therapy.
Wang L; Yao M; Zheng W; Fang M; Wu M; Sun J; Dong Z; Yao D
Mini Rev Med Chem; 2019; 19(4):272-280. PubMed ID: 30360707
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
